Logo

BG Medicine Withdraws IPO

Jan 24, 2008
NEW YORK (GenomeWeb News) — BG Medicine said yesterday that it has withdrawn its registration statement with the US Securities and Exchange Commission for an initial public offering.
 
The Waltham, Mass.-based biomarker and molecular diagnostics maker cited “current market conditions” for its decision not to proceed with the IPO. It did not elaborate on those conditions.
 
BG had intended to float its shares on the Euronext Amsterdam Exchange.
 

Breaking News
The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.